| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $20,199,404 | 3 | 12 |
Sells | $9,049,372 | 23 | 88 |
| ORBIMED ADVISORS LLC | 1 | $10M | 0 | $0 | $10M | |
| Thompson Peter A. | 1 | $10M | 0 | $0 | $10M | |
| Fox Jonathan C | director | 1 | $199,403 | 0 | $0 | $199,403 |
| Carruthers R Michael | Chief Financial Officer | 0 | $0 | 2 | $40,745 | $-40,745 |
| MOORE JOHN R | General Counsel | 0 | $0 | 2 | $59,854 | $-59,854 |
| Derakhshan Behrad | Chief Business Officer | 0 | $0 | 3 | $361,485 | $-361,485 |
| KOCH KEVIN | President and CEO | 0 | $0 | 5 | $467,438 | $-467,438 |
| Donovan Joanne M. | CMO | 0 | $0 | 3 | $814,334 | $-814,334 |
| Edris Badreddin | director | 0 | $0 | 1 | $3.4M | $-3.4M |
| Russell Alan J | Chief Scientific Officer | 0 | $0 | 7 | $3.91M | $-3.91M |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Over the last 12 months, insiders at Edgewise Therapeutics, Inc. have bought $20.2M and sold $9.05M worth of Edgewise Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Edgewise Therapeutics, Inc. have bought $28.2M and sold $7.39M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $10M. Thompson Peter A. () — $10M. Fox Jonathan C (director) — $199,403.
The last purchase of 10,700 shares for transaction amount of $199,403 was made by Fox Jonathan C (director) on 2025‑11‑11.
| 2026-01-21 | Sale | Edris Badreddin | director | 115,471 0.1098% | $29.44 | $3.4M | -2.82% | |
| 2025-11-12 | Sale | Russell Alan J | Chief Scientific Officer | 100,000 0.1163% | $21.12 | $2.11M | +12.16% | |
| 2025-11-11 | Fox Jonathan C | director | 10,700 0.011% | $18.64 | $199,403 | +10.52% | ||
| 2025-08-26 | Sale | Russell Alan J | Chief Scientific Officer | 100,000 0.0933% | $14.60 | $1.46M | +25.21% | |
| 2025-08-12 | Sale | Carruthers R Michael | Chief Financial Officer | 1,428 0.0014% | $13.39 | $19,124 | +28.16% | |
| 2025-08-12 | Sale | KOCH KEVIN | President and CEO | 7,972 0.0078% | $13.39 | $106,764 | +28.16% | |
| 2025-08-12 | Sale | Donovan Joanne M. | CMO | 2,862 0.0028% | $13.39 | $38,329 | +28.16% | |
| 2025-08-12 | Sale | Derakhshan Behrad | Chief Business Officer | 2,491 0.0024% | $13.39 | $33,360 | +28.16% | |
| 2025-08-12 | Sale | Russell Alan J | Chief Scientific Officer | 1,907 0.0019% | $13.39 | $25,539 | +28.16% | |
| 2025-08-12 | Sale | MOORE JOHN R | General Counsel | 2,098 0.0021% | $13.39 | $28,097 | +28.16% | |
| 2025-05-02 | Sale | Carruthers R Michael | Chief Financial Officer | 1,314 0.0012% | $16.45 | $21,621 | -11.62% | |
| 2025-05-02 | Sale | Donovan Joanne M. | CMO | 5,187 0.0048% | $16.45 | $85,348 | -11.62% | |
| 2025-05-02 | Sale | KOCH KEVIN | President and CEO | 4,276 0.004% | $16.45 | $70,358 | -11.62% | |
| 2025-05-02 | Sale | Derakhshan Behrad | Chief Business Officer | 1,691 0.0016% | $16.45 | $27,824 | -11.62% | |
| 2025-05-02 | Sale | Russell Alan J | Chief Scientific Officer | 1,551 0.0014% | $16.45 | $25,520 | -11.62% | |
| 2025-05-02 | Sale | MOORE JOHN R | General Counsel | 1,930 0.0018% | $16.45 | $31,757 | -11.62% | |
| 2025-04-03 | Thompson Peter A. | 496,771 0.7735% | $20.13 | $10M | +9.54% | |||
| 2025-04-03 | ORBIMED ADVISORS LLC | 496,771 0.7735% | $20.13 | $10M | +9.54% | |||
| 2025-03-07 | Sale | Russell Alan J | Chief Scientific Officer | 200 0.0002% | $30.02 | $6,004 | -46.09% | |
| 2025-03-07 | Sale | KOCH KEVIN | President and CEO | 100 0.0001% | $30.00 | $3,000 | -46.09% |
| ORBIMED ADVISORS LLC | 14809075 13.9882% | $423.69M | 5 | 0 | +0.53% | |
| Thompson Peter A. | 14809075 13.9882% | $423.69M | 5 | 0 | +0.53% | |
| Carruthers R Michael | Chief Financial Officer | 86162 0.0814% | $2.47M | 0 | 6 | |
| KOCH KEVIN | President and CEO | 30615 0.0289% | $875,895.15 | 0 | 7 | |
| Donovan Joanne M. | CMO | 25361 0.024% | $725,578.21 | 0 | 6 | |
| Fox Jonathan C | director | 23702 0.0224% | $678,114.22 | 2 | 0 | +90.07% |
| Derakhshan Behrad | Chief Business Officer | 23645 0.0223% | $676,483.45 | 0 | 9 | |
| Russell Alan J | Chief Scientific Officer | 23400 0.0221% | $669,474.00 | 0 | 37 | |
| Edris Badreddin | director | 19820 0.0187% | $567,050.20 | 0 | 1 | |
| MOORE JOHN R | General Counsel | 10214 0.0096% | $292,222.54 | 0 | 19 | |
| OrbiMed Genesis GP LLC | 13497456 12.7493% | $386.16M | 1 | 0 | +30.03% | |
| Novo Holdings A/S | 10 percent owner | 6071703 5.7351% | $173.71M | 2 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 3933137 3.7151% | $112.53M | 1 | 0 | <0.0001% |
| ROOT JONATHAN D | director | 15625 0.0148% | $447,031.25 | 1 | 0 | <0.0001% |
| Semigran Marc | Chief Development Officer | 6716 0.0063% | $192,144.76 | 0 | 1 |
$11,588,217 | 69 | 42.07% | $2.9B | |
$11,583,737 | 45 | 49.75% | $2.63B | |
$148,770,544 | 34 | 80.63% | $3.33B | |
$5,066,938 | 27 | 26.38% | $3.23B | |
$61,703,557 | 26 | 40.25% | $3.09B | |
$150,253,463 | 26 | -52.83% | $3.4B | |
$27,105,902 | 21 | -16.06% | $2.83B | |
$137,061,250 | 16 | 23.01% | $3.21B | |
$174,105,409 | 15 | 10.88% | $2.75B | |
$73,814,940 | 15 | -4.77% | $2.67B | |
Edgewise Therapeutics, Inc. (EWTX) | $92,580,864 | 14 | -1.28% | $3.03B |
$1,248,715 | 10 | 5.66% | $3.34B | |
$45,445,266 | 9 | -24.96% | $3.05B | |
$32,575,266 | 8 | 37.03% | $2.9B | |
$91,589,325 | 7 | -6.97% | $2.91B | |
$24,000,085 | 4 | 33.26% | $2.88B | |
$142,493,653 | 3 | 4.30% | $3.09B | |
$9,900,000 | 1 | -7.19% | $3.16B | |
$5,000,000 | 1 | -22.84% | $2.83B |
| Increased Positions | 80 | +38.65% | 4M | +3.35% |
| Decreased Positions | 86 | -41.55% | 11M | -8.91% |
| New Positions | 18 | New | 309,436 | New |
| Sold Out Positions | 23 | Sold Out | 3M | Sold Out |
| Total Postitions | 201 | -2.9% | 112M | -5.56% |
| Orbimed Advisors Llc | $368,564.00 | 14.64% | 15.52M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $247,675.00 | 9.84% | 10.43M | +525,804 | +5.31% | 2025-09-30 |
| Baker Bros. Advisors Lp | $173,516.00 | 6.89% | 7.31M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $150,848.00 | 5.99% | 6.35M | -429,559 | -6.33% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $146,541.00 | 5.82% | 6.17M | +27,787 | +0.45% | 2025-09-30 |
| Novo Holdings A/S | $127,063.00 | 5.05% | 5.35M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $123,757.00 | 4.92% | 5.21M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $118,259.00 | 4.7% | 4.98M | -524,018 | -9.52% | 2025-09-30 |
| Vanguard Group Inc | $114,094.00 | 4.53% | 4.8M | -37,559 | -0.78% | 2025-09-30 |
| Cormorant Asset Management, Lp | $95,238.00 | 3.78% | 4.01M | -241,992 | -5.69% | 2025-09-30 |